Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (13106)	1/8/1998 8:49:00 PM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

Andy, I did a search and found nothing for mycopia. It's probably spelled wrong, but I have no idea of the correct spelling. Speaking of trials, I found this old (April, 1996) announcement of a Targretin Head & Neck trial at MD Anderson, which I think is where the sky diver enrolled (he had cancer of the tongue and month and also had a remarkable recovery after failure of chemotherapy): M. D. Anderson Cancer Center is conducting a trial of a new drug, LGD 1069 (TARGRETIN <tm> capsules). The purpose of the trial is to determine how well patients with advanced head/neck squamous cell cancer tolerate treatment with LGD 1069. Investigators will also determine if tumors shrink with this treatment. LGD 1069 will be provided free of charge by the study sponsor, Ligand Pharmaceuticals. It is possible that this treatment may reduce the size of a tumor, which could result in increased comfort and help patients live longer. This is an experimental drug trial. For more information about the study, or for information on how to register, call or write: Fadlo Khuri, MD or Lori Martinez, RN The University of Texas M D Anderson Cancer Center 1515 Holcombe Blvd., Box 80 Houston, TX 77030 (713) 792-6363 The Dept. of Thoracic/Head & Neck Medical Oncology at M D Anderson